What is North China Pharmaceutical Company.Ltd's (600812.SS) StockRank?

MoatMap's StockRank for North China Pharmaceutical Company.Ltd (600812.SS) is 20/100, with a Sell signal. This is a composite score combining Quality (41), Value (38), and Momentum (31) factor ranks across MoatMap's 20,000+ stock universe.

Does North China Pharmaceutical Company.Ltd have an economic moat?

North China Pharmaceutical Company.Ltd (600812.SS) has a Quality factor score of 41/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is North China Pharmaceutical Company.Ltd a buy, hold, or sell?

MoatMap's current signal for North China Pharmaceutical Company.Ltd (600812.SS) is Sell, based on a StockRank of 20/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is North China Pharmaceutical Company.Ltd in?

North China Pharmaceutical Company.Ltd (600812.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

600812.SS

SELLREMOVE

North China Pharmaceutical Company.Ltd · Healthcare · China · $1.2B · Avg Vol: $9M/d

StockRank

P/E (TTM)

49.8x

ROE

3.4%

D/E

1.6x

Dividend %

0.8%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

North China Pharmaceutical is a state-owned generic drug and API manufacturer. It suffers from low margins, high capital intensity, and low quality metrics (Q: 41), failing to exhibit the proprietary technology or pricing power of high-end CDMOs.

COMPANY DESCRIPTION

North China Pharmaceutical Company Ltd. manufactures antibiotics, biopharmaceuticals, and veterinary medicines. As a historic pioneer in China's pharmaceutical industry, it maintains massive production capacity for penicillin and cephalosporins. The company is a state-owned generic drug giant with a highly integrated supply chain from APIs to finished formulations.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	1.6B	1.5B	1.5B	1.4B	-4.2%
EPS	-0.06	0.00	0.01	0.02	497.2%
Shares	1.7B	1.7B	1.7B	1.7B	0.0%
Debt	1.6B	1.6B	1.7B	1.7B	0.5%
Equity	783M	786M	797M	815M	1.3%
Op CF	148M	151M	182M	174M	5.4%
Inv CF	-78M	-130M	-140M	-115M	—
Fin CF	-662M	-104M	68M	-57M	—

PRICE (1M)-16.8%

SMA 50SMA 200

$0.65

RSI (14)

41.7

52W High

$1.09

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

8.0%67.0

ROE

3.4%51.9

GP/Assets

12.9%31.5

Op. Margin

5.9%57.3

FCF/Assets

0.7%53.0

Piotroski

—55.7

Int. Cover

2.0x45.3

D/E Ratio

1.62x7.5

Current Ratio

0.72x4.1

Value

P/E (TTM)

49.8x20.5

EV/EBITDA

12.7x33.9

P/FCF

330.3x23.3

P/B

1.4x69.0

P/S

0.9x86.1

Div Yield

0.8%22.2

Momentum

52W High %

59%38.0

RS 6M

-33%38.0

SMA 50/200

0.89x30.7

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

-38%15.0

FUNDAMENTALS

Market Cap

$1.2B

P/E (Forward)

—

Gross Margin

31.1%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 600812.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
600812.SS	North China Pharmaceutical Company.Ltd(you)	$1.2B	20	SELL
600129.SS	Chongqing Taiji Industry(Group) Co.,Ltd	$1.2B	22	SELL
688221.SS	Frontier Biotechnologies Inc.	$1.1B	22	SELL
688276.SS	Changchun BCHT Biotechnology Co.	$975M	21	SELL
002099.SZ	Zhejiang Hisoar Pharmaceutical Co., Ltd.	$1.3B	18	STRONG SELL
600422.SS	KPC Pharmaceuticals,Inc.	$999M	23	SELL
300363.SZ	Porton Pharma Solutions Ltd.	$1.2B	25	SELL
002940.SZ	Zhejiang AngLiKang Pharmaceutical CO.,LTD.	$1.0B	25	SELL
603567.SS	Heilongjiang ZBD Pharmaceutical Co., Ltd.	$994M	25	SELL
6185.HK	CanSino Biologics Inc.	$814M	19	STRONG SELL

Peer medians: ROE 4.8% · P/E 27.6x · Gross margin 53.1%

North China Pharmaceutical Company.Ltd (600812.SS) — Stock Score Summary

North China Pharmaceutical Company.Ltd (600812.SS) has a MoatMap StockRank of 20/100 based on Quality (41/100), Value (38/100), and Momentum (31/100) factor scores. The current signal is SELL. North China Pharmaceutical is a state-owned generic drug and API manufacturer. It suffers from low margins, high capital intensity, and low quality metrics (Q: 41), failing to exhibit the proprietary technology or pricing power of high-end CDMOs.

Key Financial Metrics

Price	$0.65
Market Cap	$1.2B
P/E (TTM)	49.78
Price/Book	1.38
Return on Equity	3.4%
Return on Invested Capital	8.0%
Debt/Equity	162.06
Gross Margin	31.1%
Operating Margin	5.9%
Revenue Growth	-16.4%
Dividend Yield	0.8%
Free Cash Flow	$3M

North China Pharmaceutical Company.Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is North China Pharmaceutical Company.Ltd’s (600812.SS) StockRank?: MoatMap’s StockRank for North China Pharmaceutical Company.Ltd (600812.SS) is 20/100, with a Sell signal. It is a composite of Quality (41), Value (38), and Momentum (31) factor ranks across MoatMap’s 20,000+ stock universe.
Does North China Pharmaceutical Company.Ltd have an economic moat?: North China Pharmaceutical Company.Ltd (600812.SS) has a Quality factor score of 41/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is North China Pharmaceutical Company.Ltd a buy, hold, or sell?: MoatMap’s current signal for North China Pharmaceutical Company.Ltd (600812.SS) is Sell, based on a StockRank of 20/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is North China Pharmaceutical Company.Ltd in?: North China Pharmaceutical Company.Ltd (600812.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).